Skip to main content
. Author manuscript; available in PMC: 2023 Jan 12.
Published in final edited form as: Lancet Microbe. 2023 Jan;4(1):e38–e46. doi: 10.1016/S2666-5247(22)00296-8

Figure 3: Discovery of four undiagnosed cases of SARS-CoV-2 in Connecticut, USA (March, 2020).

Figure 3:

(A) SARS-CoV-2 positive tests during March, 2020, according to publicly available data.22-24 SARS-CoV-2 testing began at Yale New Haven Hospital on March 13, 2020. Screening was performed between March 3 and March 14, 2020. (B) In all negative samples on the multiplex viral PCR panel, CXCL10 was measured by ELISA (biomarker-based screening) and SARS-CoV-2 (N1 gene) was measured by RT-qPCR. (C) Four discovered SARS-CoV-2 positive samples shown (red) with corresponding NextStrain codes. The dotted line indicates the proportion of samples with nasopharyngeal CXCL10 concentration of 100 pg/mL or higher.